Company

GenFleet's Oral Pan‑RAS Inhibitor GFH276 Clears Multiple CTAs in China and Australia – Innovative Combination Trials Advance Across RAS‑Mutant Solid Tumors
Clinical trial approval / initiationGenFleet Therapeutics

GenFleet’s Oral Pan‑RAS Inhibitor GFH276 Clears Multiple CTAs in China and Australia – Innovative Combination Trials Advance Across RAS‑Mutant Solid Tumors

GenFleet Therapeutics (Shanghai) Inc. (HKG: 2595) announced that multiple innovative combination therapies of its oral pan‑RAS inhibitor GFH276 have received Clinical Trial Authorizations (CTA) from the Center for Drug Evaluation…

CMS Subsidiary Rxilient Medical Wins Singapore HSA Approval for Lumirix in Vitiligo – First Regional Indication Expansion for the Topical JAK Inhibitor Licensed from Incyte

CMS Subsidiary Rxilient Medical Wins Singapore HSA Approval for Lumirix in Vitiligo – First Regional Indication Expansion for the Topical JAK Inhibitor Licensed from Incyte

CSPC Pharmaceutical Initiates Phase II Trial of SYH2072 – Self‑Developed Aldosterone Synthase Inhibitor Targeting Uncontrolled and Refractory Hypertension in China

CSPC Pharmaceutical Initiates Phase II Trial of SYH2072 – Self‑Developed Aldosterone Synthase Inhibitor Targeting Uncontrolled and Refractory Hypertension in China

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
BiosimilarsCancer

Henlius Biotech’s Perjeta Biosimilar HLX11 (Poherdy) Secures NMPA Approval for HER2-Positive Breast Cancer in China

True Health Medical Files Hong Kong IPO for Percutaneous Surgery Robot Portfolio with Multiple China-First Innovations
CancerIPO

True Health Medical Files Hong Kong IPO for Percutaneous Surgery Robot Portfolio with Multiple China-First Innovations

Clinical trial approval / initiationKanghua Biological Products

Chengdu Kanghua Initiates Phase II Trial for RSV mRNA Vaccine Through NanoRibo Acquisition in China’s Untapped Market

AbbVie's VENCLYXTO Receives European Commission Approval for Two Novel Fixed-Duration Combinations in First-Line CLL Treatment
AbbVieNYSE: ABBV

AbbVie’s VENCLYXTO Receives European Commission Approval for Two Novel Fixed-Duration Combinations in First-Line CLL Treatment

Show More